# NCT03113643 (NCT03113643)

> SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03113643
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions: Azacitidine; SL-401; Venetoclax
- Enrollment: 72
- Primary outcome: Maximum Tolerated Dose

## Indexed commentary on NCT03113643 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03113643